Phase I-II trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study

J. W. Myers, W. A. Knight, Robert B Livingston, C. Fabian, J. Costanzi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Forty-four patients with advanced colon or rectal cancer were treated with methyl-GAG on a weekly schedule. Of the 40 evaluable patients, 35 (87%) had received prior chemotherapy. Objective tumor regression was seen in six patients (one Cr, five PR's). An additional nine patients had stable disease for a median of 42 weeks. The median survival (42+ weeks) for responding and stable disease patients was significantly better (p = 0.0001 Wilcoxan test) than those with progressive disease (11 weeks). Toxicity was reversible and included mild to moderate mucositis, nausea, vomiting, diarrhea, and thrombocytopenia. Responses observed in this study warrant further trials in patients with colon cancer who have received no prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)277-279
Number of pages3
JournalCancer Clinical Trials
Volume4
Issue number3
StatePublished - 1981
Externally publishedYes

Fingerprint

Colonic Neoplasms
Drug Therapy
Mucositis
Rectal Neoplasms
Thrombocytopenia
Nausea
Vomiting
Diarrhea
Appointments and Schedules
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phase I-II trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study. / Myers, J. W.; Knight, W. A.; Livingston, Robert B; Fabian, C.; Costanzi, J.

In: Cancer Clinical Trials, Vol. 4, No. 3, 1981, p. 277-279.

Research output: Contribution to journalArticle

Myers, J. W. ; Knight, W. A. ; Livingston, Robert B ; Fabian, C. ; Costanzi, J. / Phase I-II trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study. In: Cancer Clinical Trials. 1981 ; Vol. 4, No. 3. pp. 277-279.
@article{3cc2e55f6bab408e84cefa48cb6c81c9,
title = "Phase I-II trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study",
abstract = "Forty-four patients with advanced colon or rectal cancer were treated with methyl-GAG on a weekly schedule. Of the 40 evaluable patients, 35 (87{\%}) had received prior chemotherapy. Objective tumor regression was seen in six patients (one Cr, five PR's). An additional nine patients had stable disease for a median of 42 weeks. The median survival (42+ weeks) for responding and stable disease patients was significantly better (p = 0.0001 Wilcoxan test) than those with progressive disease (11 weeks). Toxicity was reversible and included mild to moderate mucositis, nausea, vomiting, diarrhea, and thrombocytopenia. Responses observed in this study warrant further trials in patients with colon cancer who have received no prior chemotherapy.",
author = "Myers, {J. W.} and Knight, {W. A.} and Livingston, {Robert B} and C. Fabian and J. Costanzi",
year = "1981",
language = "English (US)",
volume = "4",
pages = "277--279",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phase I-II trial of methyl-GAG in advanced colon cancer. A Southwest Oncology Group pilot study

AU - Myers, J. W.

AU - Knight, W. A.

AU - Livingston, Robert B

AU - Fabian, C.

AU - Costanzi, J.

PY - 1981

Y1 - 1981

N2 - Forty-four patients with advanced colon or rectal cancer were treated with methyl-GAG on a weekly schedule. Of the 40 evaluable patients, 35 (87%) had received prior chemotherapy. Objective tumor regression was seen in six patients (one Cr, five PR's). An additional nine patients had stable disease for a median of 42 weeks. The median survival (42+ weeks) for responding and stable disease patients was significantly better (p = 0.0001 Wilcoxan test) than those with progressive disease (11 weeks). Toxicity was reversible and included mild to moderate mucositis, nausea, vomiting, diarrhea, and thrombocytopenia. Responses observed in this study warrant further trials in patients with colon cancer who have received no prior chemotherapy.

AB - Forty-four patients with advanced colon or rectal cancer were treated with methyl-GAG on a weekly schedule. Of the 40 evaluable patients, 35 (87%) had received prior chemotherapy. Objective tumor regression was seen in six patients (one Cr, five PR's). An additional nine patients had stable disease for a median of 42 weeks. The median survival (42+ weeks) for responding and stable disease patients was significantly better (p = 0.0001 Wilcoxan test) than those with progressive disease (11 weeks). Toxicity was reversible and included mild to moderate mucositis, nausea, vomiting, diarrhea, and thrombocytopenia. Responses observed in this study warrant further trials in patients with colon cancer who have received no prior chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0019796312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019796312&partnerID=8YFLogxK

M3 - Article

C2 - 7285275

AN - SCOPUS:0019796312

VL - 4

SP - 277

EP - 279

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -